Low galectin-3 capacity to discriminate thyroid lesions

被引:0
作者
De-León-Mazariegos, R
Canedo-Patzi, M
Pérez-Enríquez, B
Candanedo-Gonzalez, F
Saqui-Salces, M
Gamboa-Domínguez, A
Rull-Rodrigo, JA
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Patol, Mexico City 14000, DF, Mexico
[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Clin Tiroides, Mexico City 14000, DF, Mexico
[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Direcc Med, Mexico City 14000, DF, Mexico
来源
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2004年 / 56卷 / 05期
关键词
galectin-3; thyroid; sensibility; specificity; ROC curve;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Galectin-3 is considered useful in identifying lesions included in the term follicular tumour. Objective. To evaluate galectin-3's power to discriminate among diverse thyroid lesions and to identify a set point of expression at which there is the least possible false positive results. Methods. 26 follicular carcinomas and 104 assorted thyroid lesions were analysed (8 Hashimoto's thyroiditis, 18 goiter, 44 adenoma, 27 papillary carcinoma and 7 normal glands). Immunohistochemistry for galectin-3 was pet-formed way (NCL-GAL-3, 1:100, Novocastra, UK). In a blinded manner intensity and percentage of expression were evaluated, as was its capacity to identify the previously mentioned thyroid entities with 2 x 2 tables. Minimum reactivity set point values were identified and the one which presented the least false positive cases was selected. Results. A reaction was considered positive when 25% of the cells were marked, in which case neither the Hashimoto's thyroiditis, goiter, nor the residual tissue were positive for galectin-3. A positive galectin-3 reaction was identified in 4144 adenomas, 5126 follicular carcinomas and 18127 papillary carcinomas. From a total of 53 carcinomas, 23 showed positive and 30 a negative reaction to galectin-3. Thus, galectin-3s sensitivity to discriminate between benign and malignant lesions was 94% while its specificity was 43%. When comparing follicular carcinoma with adenoma, sensibility was 19% while specificity was 91%. The positive predictive value was 56% and the negative predictive value 66%. Galectin-3 was most useful for identifying papillary thyroid carcinoma. Conclusions. Galectin-3 has limited value to distinguish benign from malignant thyroid lesions. The reaction must be considered positive when at least 25% of cells are marked.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 22 条
[1]   Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions [J].
Bartolazzi, A ;
Gasbarri, A ;
Papotti, M ;
Bussolati, G ;
Lucante, T ;
Khan, A ;
Inohara, H ;
Marandino, F ;
Orlandi, F ;
Nardi, F ;
Vecchione, A ;
Tecce, R ;
Larsson, O .
LANCET, 2001, 357 (9269) :1644-1650
[2]   Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction [J].
Bernet, VJ ;
Anderson, J ;
Vaishnav, Y ;
Solomon, B ;
Adair, CF ;
Saji, M ;
Burman, KD ;
Burch, HB ;
Ringel, MD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4792-4796
[3]   Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia [J].
Coli, A ;
Bigotti, G ;
Zucchetti, F ;
Negro, F ;
Massi, G .
HISTOPATHOLOGY, 2002, 40 (01) :80-87
[4]  
Cvejic D, 1998, ANTICANCER RES, V18, P2637
[5]  
DAVIES R, 2003, CYTOPATHOLOGY, pS14
[6]   Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry [J].
Feilchenfeldt, J ;
Tötsch, M ;
Sheu, SY ;
Robert, J ;
Spiliopoulos, A ;
Frilling, A ;
Schmid, KW ;
Meier, CA .
MODERN PATHOLOGY, 2003, 16 (11) :1117-1123
[7]  
Fernandez PL, 1997, J PATHOL, V181, P80
[8]   Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland [J].
Gaffney, RL ;
Carney, JA ;
Sebo, TJ ;
Erickson, LA ;
Volante, M ;
Papotti, M ;
Lloyd, RV .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (04) :494-498
[9]   Macrofollicular variant of papillary thyroid carcinoma: A case and control analysis [J].
GamboaDominguez, A ;
VieitezMartinez, I ;
BarredoPrieto, BA ;
RichaudPatin, Y ;
Herrera, MF ;
AngelesAngeles, A .
ENDOCRINE PATHOLOGY, 1996, 7 (04) :303-308
[10]  
GamboaDominguez A, 1997, ACTA CYTOL, V41, P672